XNAS · Healthcare · Biotechnology
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | -71.40 | -13.60 | +80.95% | $20.3M | ❌ Miss | -9.50% | -13.08% | — |
| 2026-04-07 | Q4 2025 | -4.26 | -0.36 | +91.55% | $3.4M | ✅ Beat | +0.00% | -0.85% | -79.21% |
| 2025-11-17 |
| Q3 2025 |
| -4.26 |
| -6.28 |
| -47.42% |
| $3.1M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -7.13 | -10.25 | -43.76% | $3.0M | ❌ Miss | -1.16% | -12.08% | -5.31% |
| 2025-03-31 | Q4 2024 | -18.50 | -8.44 | +54.38% | $3.5M | ✅ Beat | +0.00% | +0.63% | +157.14% |
| 2024-11-13 | Q3 2024 | -59.25 | -26.25 | +55.70% | $3.1M | ✅ Beat | +5.31% | -0.78% | -1.85% |
| 2024-08-13 | Q2 2024 | -27.75 | -101.00 | -263.96% | $2.7M | ❌ Miss | +0.00% | +10.28% | +3.74% |
| 2024-05-14 | Q1 2024 | -0.75 | -1.50 | -100.00% | $2.4M | ❌ Miss | -7.20% | -48.13% | -77.51% |
Showing last 8 quarters.